Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Aug;64(2):267–273. doi: 10.1038/bjc.1991.290

Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

L A Speicher 1, V R Sheridan 1, A K Godwin 1, K D Tew 1
PMCID: PMC1977526  PMID: 1892755

Abstract

Following EMS mutagenesis, three estramustine (EM) resistant DU 145 human prostatic carcinoma cell lines were clonally selected by exposure to incrementally increasing concentrations of the drug. Although only low levels of resistance (approximately 3-fold) were attainable, this resistance was stable in the absence of continuous drug exposure. These EM-resistant clones (EMR 4,9,12) did not exhibit cross resistance to vinblastine, taxol, or adriamycin, and had collateral sensitivity to cytochalasin B. None of the lines had elevated expression of P-glycoprotein mRNA or glutathione S-transferase activity, suggesting a phenotype distinct from the classic multi-drug resistance phenotype. This conclusion was supported further by the observation that two MDR cell lines (FLC mouse erythroleukaemic and SKOV3 human ovarian carcinoma cells) showed sensitivity to EM. Fluorescent activated cell sorting analysis of the effects of EM on cell cycle traverse revealed that at EM concentrations up to 20 microM an increasing percentage of wild type cells were blocked in G2/M; no such effect occurred in EMR lines. Differential interference contrast microscopy was employed to study EM's effect on mitosis. EMR lines were able to form functional, albeit smaller, spindles at EM concentrations that resulted in chromosomal disorganisation and inhibition of mitotic progression in wild type cells. EMR lines were able to progress through mitosis and cytokinesis at the same rate as untreated cells. Tritiated EM was used to evaluate potential drug uptake/efflux mutations in ERM clones. EMR 4 and 9 incorporate less EM than wild type cells; however, they have significantly decreased cellular volumes. The initial efflux rate constants for EMR clones were greater than for wild type cells. Within 5 min greater than 70% of the drug was lost from resistant cells compared to a 50% loss by the wild type. Although the specific mechanisms of resistance have yet to be defined, the lack of collateral resistance to other MDR/anti-microtubule agents could serve as the basis for the clinical use of EM in combination chemotherapy.

Full text

PDF
267

Images in this article

270Figure 3
on p.270
271Figure 5
on p.271

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Batist G., Tulpule A., Sinha B. K., Katki A. G., Myers C. E., Cowan K. H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986 Nov 25;261(33):15544–15549. [PubMed] [Google Scholar]
  2. Bech-Hansen N. T., Till J. E., Ling V. Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol. 1976 May;88(1):23–31. doi: 10.1002/jcp.1040880104. [DOI] [PubMed] [Google Scholar]
  3. Beck W. T. Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts. Cancer Treat Rep. 1983 Oct;67(10):875–882. [PubMed] [Google Scholar]
  4. Björk P., Forsgren B., Gustafsson J. A., Pousette A., Högberg B. Partial characterization and "quantitation" of a human prostatic estramustine-binding protein. Cancer Res. 1982 May;42(5):1935–1942. [PubMed] [Google Scholar]
  5. Bradley G., Naik M., Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res. 1989 May 15;49(10):2790–2796. [PubMed] [Google Scholar]
  6. Bryan J. Vinblastine and microtubules. I. Induction and isolation of crystals from sea urchin oocytes. Exp Cell Res. 1971 May;66(1):129–136. doi: 10.1016/s0014-4827(71)80020-4. [DOI] [PubMed] [Google Scholar]
  7. Cabral F., Barlow S. B. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J. 1989 Mar;3(5):1593–1599. doi: 10.1096/fasebj.3.5.2646163. [DOI] [PubMed] [Google Scholar]
  8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  9. Forsgren B., Björk P., Carlström K., Gustafsson J. A., Pousette A., Högberg B. Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivative of estradiol-17 beta. Proc Natl Acad Sci U S A. 1979 Jul;76(7):3149–3153. doi: 10.1073/pnas.76.7.3149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Forsgren B., Björk P. Specific binding of estramustine to prostatic proteins. Urology. 1984 Jun;23(6 Suppl):34–38. doi: 10.1016/s0090-4295(84)80095-3. [DOI] [PubMed] [Google Scholar]
  11. Forsgren B., Gustafsson J. A., Pousette A., Högberg B. Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivative of 17 beta-estradiol. Cancer Res. 1979 Dec;39(12):5155–5164. [PubMed] [Google Scholar]
  12. Griffith L. M., Pollard T. D. Evidence for actin filament-microtubule interaction mediated by microtubule-associated proteins. J Cell Biol. 1978 Sep;78(3):958–965. doi: 10.1083/jcb.78.3.958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Griffith O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem. 1980 Jul 15;106(1):207–212. doi: 10.1016/0003-2697(80)90139-6. [DOI] [PubMed] [Google Scholar]
  14. Gunnarsson P. O., Andersson S. B., Johansson S. A., Nilsson T., Plym-Forshell G. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. Eur J Clin Pharmacol. 1984;26(1):113–119. doi: 10.1007/BF00546718. [DOI] [PubMed] [Google Scholar]
  15. Gunnarsson P. O., Forshell G. P., Fritjofsson A., Norlén B. J. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt). Scand J Urol Nephrol. 1981;15(3):201–205. doi: 10.3109/00365598109179603. [DOI] [PubMed] [Google Scholar]
  16. Habig W. H., Pabst M. J., Jakoby W. B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974 Nov 25;249(22):7130–7139. [PubMed] [Google Scholar]
  17. Hartley-Asp B. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate. 1984;5(1):93–100. doi: 10.1002/pros.2990050109. [DOI] [PubMed] [Google Scholar]
  18. Hartley-Asp B., Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate. 1986;9(4):387–395. doi: 10.1002/pros.2990090408. [DOI] [PubMed] [Google Scholar]
  19. Jönsson G., Högberg B., Nilsson T. Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt). Scand J Urol Nephrol. 1977;11(3):231–238. doi: 10.3109/00365597709179957. [DOI] [PubMed] [Google Scholar]
  20. Kanje M., Deinum J., Wallin M., Ekström P., Edström A., Hartley-Asp B. Effect of estramustine phosphate on the assembly of isolated bovine brain microtubules and fast axonal transport in the frog sciatic nerve. Cancer Res. 1985 May;45(5):2234–2239. [PubMed] [Google Scholar]
  21. Kartner N., Shales M., Riordan J. R., Ling V. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res. 1983 Sep;43(9):4413–4419. [PubMed] [Google Scholar]
  22. Kimura I. Further evidence of the similarity of microtubule protein from mitotic apparatus and sperm tail of the sea urchin, as a substrate in thiol-disulfide exchange reaction. Exp Cell Res. 1973 Jun;79(2):445–446. doi: 10.1016/0014-4827(73)90464-3. [DOI] [PubMed] [Google Scholar]
  23. Kruse E., Hartley-Asp B. A time study on the uptake of estramustine into prostatic tumour 1013L cells in vitro. Biochem Pharmacol. 1989 Feb 15;38(4):702–704. doi: 10.1016/0006-2952(89)90221-9. [DOI] [PubMed] [Google Scholar]
  24. Küss R., Khoury S., Richard F., Fourcade F., Frantz P., Capelle J. P. Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol. 1980 Feb;52(1):29–33. doi: 10.1111/j.1464-410x.1980.tb02915.x. [DOI] [PubMed] [Google Scholar]
  25. Ling V. Drug resistance and membrane alteration in mutants of mammalian cells. Can J Genet Cytol. 1975 Dec;17(4):503–515. doi: 10.1139/g75-064. [DOI] [PubMed] [Google Scholar]
  26. Ling V., Thompson L. H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol. 1974 Feb;83(1):103–116. doi: 10.1002/jcp.1040830114. [DOI] [PubMed] [Google Scholar]
  27. MacLean-Fletcher S., Pollard T. D. Mechanism of action of cytochalasin B on actin. Cell. 1980 Jun;20(2):329–341. doi: 10.1016/0092-8674(80)90619-4. [DOI] [PubMed] [Google Scholar]
  28. Mareel M. M., Storme G. A., Dragonetti C. H., De Bruyne G. K., Hartley-Asp B., Segers J. L., Rabaey M. L. Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro. Cancer Res. 1988 Apr 1;48(7):1842–1849. [PubMed] [Google Scholar]
  29. Onfelt A. Spindle disturbances in mammalian cells. I. Changes in the quantity of free sulfhydryl groups in relation to survival and C-mitosis in V79 Chinese hamster cells after treatment with colcemid, diamide, carbaryl and methyl mercury. Chem Biol Interact. 1983 Sep 1;46(2):201–217. doi: 10.1016/0009-2797(83)90029-7. [DOI] [PubMed] [Google Scholar]
  30. Riordan J. R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. 1985 Aug 29-Sep 4Nature. 316(6031):817–819. doi: 10.1038/316817a0. [DOI] [PubMed] [Google Scholar]
  31. Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly in vitro by taxol. Nature. 1979 Feb 22;277(5698):665–667. doi: 10.1038/277665a0. [DOI] [PubMed] [Google Scholar]
  32. Schiff P. B., Horwitz S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561–1565. doi: 10.1073/pnas.77.3.1561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schisselbauer J. C., Crescimanno M., D'Alessandro N., Clapper M., Toulmond S., Tapiero H., Tew K. D. Glutathione, glutathione S-transferases, and related redox enzymes in Adriamycin-resistant cell lines with a multidrug resistant phenotype. Cancer Commun. 1989;1(2):133–139. doi: 10.3727/095535489820875291. [DOI] [PubMed] [Google Scholar]
  34. Selden S. C., Pollard T. D. Phosphorylation of microtubule-associated proteins regulates their interaction with actin filaments. J Biol Chem. 1983 Jun 10;258(11):7064–7071. [PubMed] [Google Scholar]
  35. Sheridan V. R., Speicher L. A., Tew K. D. The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells. Eur J Cell Biol. 1991 Apr;54(2):268–276. [PubMed] [Google Scholar]
  36. Shioda M., Murofushi H., Murakami-Murofushi K., Sakai H. Microtubule-associated protein-2 stimulates DNA synthesis catalyzed by the nuclear matrix. Biochem Biophys Res Commun. 1989 Mar 15;159(2):834–841. doi: 10.1016/0006-291x(89)90070-3. [DOI] [PubMed] [Google Scholar]
  37. Stearns M. E., Tew K. D. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res. 1985 Aug;45(8):3891–3897. [PubMed] [Google Scholar]
  38. Stearns M. E., Tew K. D. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci. 1988 Mar;89(Pt 3):331–342. doi: 10.1242/jcs.89.3.331. [DOI] [PubMed] [Google Scholar]
  39. Tapiero H., Munck J. N., Fourcade A., Lampidis T. J. Cross-resistance to rhodamine 123 in Adriamycin- and daunorubicin-resistant Friend leukemia cell variants. Cancer Res. 1984 Dec;44(12 Pt 1):5544–5549. [PubMed] [Google Scholar]
  40. Tew K. D., Erickson L. C., White G., Wang A. L., Schein P. S., Hartley-Asp B. Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets. Mol Pharmacol. 1983 Sep;24(2):324–328. [PubMed] [Google Scholar]
  41. Tew K. D., Hartley-Asp B. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology. 1984 Jun;23(6 Suppl):28–33. doi: 10.1016/s0090-4295(84)80094-1. [DOI] [PubMed] [Google Scholar]
  42. Tew K. D., Kyle G., Johnson A., Wang A. L. Carbamoylation of glutathione reductase and changes in cellular and chromosome morphology in a rat cell line resistant to nitrogen mustards but collaterally sensitive to nitrosoureas. Cancer Res. 1985 May;45(5):2326–2333. [PubMed] [Google Scholar]
  43. Tew K. D. The mechanism of action of estramustine. Semin Oncol. 1983 Sep;10(3 Suppl 3):21–26. [PubMed] [Google Scholar]
  44. Tew K. D., Woodworth A., Stearns M. E. Relationship of glutathione depletion and inhibition of glutathione-S-transferase activity to the antimitotic properties of estramustine. Cancer Treat Rep. 1986 Jun;70(6):715–720. [PubMed] [Google Scholar]
  45. Vindeløv L. L., Christensen I. J., Nissen N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):323–327. doi: 10.1002/cyto.990030503. [DOI] [PubMed] [Google Scholar]
  46. Wang A. L., Tew K. D. Increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards. Cancer Treat Rep. 1985 Jun;69(6):677–682. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES